<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00889590</url>
  </required_header>
  <id_info>
    <org_study_id>P08.185</org_study_id>
    <nct_id>NCT00889590</nct_id>
  </id_info>
  <brief_title>Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)</brief_title>
  <acronym>HR-GCT</acronym>
  <official_title>Adjuvant Zoledronic Acid in 'High Risk' Giant Cell Tumour of Bone (GCT) - A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomised phase II trial in patients with high risk GCT.

      Primary objective:

        -  Determine if adjuvant zoledronic acid improves the 2 years recurrence rate of 'high
           risk' GCT as compared to standard care

      Secondary objectives:

        -  Determine the relapse free survival

        -  Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GCT is a potentially malignant tumour that presents with a locally destructive osteolytic
      lesion. The high risk GCT are characterized by a high recurrence rate around the 40-45%.
      Zoledronic acid is a potent inhibitor of osteolysis and is capable of inducing osteoclast and
      stromal cell apoptosis, which makes it an attractive adjuvant treatment in 'high risk' GCT in
      order to improve clinical outcomes and reduce the recurrence rate.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low recruitment with registration denosumab
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the relapse free survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Giant Cell Tumor of Bone</condition>
  <condition>Osteoclastoma</condition>
  <arm_group>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant zoledronic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery</description>
    <arm_group_label>Zoledronic acid</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Male or female &gt; 18 years of age

          -  Histologically proven GCT treated with surgery

          -  High risk GCT defined as minimal one or more of the following:

               -  Recurrent GCT

               -  GCT located in the pelvis, sacrum, spine, distal ulna or growth in soft tissue

               -  GCT grade III

               -  Pathological fracture in GCT

               -  Absence of local adjuvant therapy (cryosurgery or phenol instillation)

          -  Neutrophils &gt; 1.5x109/L, platelets &gt; 100x109/L, and Hb &gt; 6 mmol/l

          -  Bilirubin level &lt; 1.5 x ULN

          -  ASAT and ALAT &lt; 2.5 x ULN

          -  Adequate renal function as defined by: serum creatinine clearance &gt; 60 cc/min

          -  Expected adequacy of follow-up

        Exclusion Criteria:

          -  Unresectable or metastatic GCT and grade IV GCT

          -  Prior bisphosphonate usage, except preoperative treatment with zoledronic acid up to 3
             months before surgery

          -  Other previous malignancy within 5 years, with exception of a history of a previous
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix

          -  Known hypersensitivity reaction to any of the components of the treatment

          -  Pregnancy or lactating

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or sign meaningful informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J R Kroep, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center (LUMC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P D Dijkstra, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A H Taminiau, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P C Hogendoorn, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H Gelderblom, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N A Hamdy, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S E Papapoulos, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University hospital Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1100DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groningen University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.R. Kroep</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>GCT</keyword>
  <keyword>Bisfosfonates</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Giant Cell Tumors</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Giant Cell Tumor of Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

